Finance

Beta
Lists
ALT:NASDAQ
Altimmune Inc
$2.82
-1.74%
(-0.050) 1D
$2.80
-0.71% (-0.020)
After hours
Closed: Jun 26, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALT...
Open
$2.85
High
$2.90
Low
$2.74
Mkt. cap
548.42M
Avg. vol.
3.31M
Volume
17.11M
52-wk high
$6.44
52-wk low
$2.56
EPS
-$0.92
Beta
0.22
Shares outstanding
194.47M
No. of employees
57
Open
$2.85
High
$2.90
Low
$2.74
Mkt. cap
548.42M
Avg. vol.
3.31M
Volume
17.11M
52-wk high
$6.44
52-wk low
$2.56
EPS
-$0.92
Beta
0.22
Shares outstanding
194.47M
No. of employees
57
News stories
From sources across the web
About Altimmune Inc
CEOJerry Durso
Employees57
Founded1997
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitealtimmune.com
Analyst ratings
Based on 7 analysts giving stock ratings to ALT in the past 3 months
Buy
Buy
5
Hold
2
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for ALT in the last 3 months.
Highest
Current $2.82
$20.00 (+609.22%)
Average
$12.70 (+350.35%)
Lowest
$2.50 (-11.35%)
Analyst
Recommendation
Action
Price target
Projected
Date
Thomas Smith
Leerink Partners
Buy
Initiated
$10.00
+254.6%
06/22/2026
Patrick Trucchio
H.C. Wainwright
Buy
Maintained
$20.00
+609.2%
06/03/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
05/29/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$11.00
+290.1%
05/14/2026
Eliana Merle
Barclays
Buy
Maintained
$20.00
+609.2%
05/14/2026
Andy Hsieh
William Blair
Hold
Reiterated
-
-
05/13/2026
Corinne Johnson
Goldman Sachs
Hold
Upgraded
$2.50
-11.3%
04/24/2026
William Wood
B. Riley Securities
Buy
Maintained
$13.00
+361%
03/06/2026
Boris Peaker
JonesTrading
Buy
Initiated
$7.00
+148.2%
02/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
5.00K
5.00K
26.00K
-
Cost of goods sold
17.24M
14.96M
18.41M
15.48M
Cost of revenue
17.24M
14.96M
18.41M
15.48M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.69M
5.90M
10.51M
8.05M
Operating expense
5.69M
5.90M
10.51M
8.05M
Total operating expenses
22.93M
20.86M
28.92M
23.54M
Operating income
-22.92M
-20.86M
-28.89M
-23.54M
Other non operating income
-92.00K
-86.00K
-27.00K
-152.00K
EBT including unusual items
-22.15M
-19.01M
-27.36M
-22.56M
EBT excluding unusual items
-22.15M
-19.01M
-27.36M
-21.85M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-22.15M
-19.01M
-27.36M
-22.56M
Net profit margin
-442,920.00%
-380,280.00%
-105,223.08%
-
Earnings per share
-0.27
-0.21
-0.27
-0.18
Interest and investment income
1.13M
2.43M
2.44M
2.90M
Interest expense
-264.00K
-495.00K
-876.00K
-1.07M
Net interest expenses
868.00K
1.93M
1.56M
1.83M
Depreciation and amortization charges
-
-
-
-
EBITDA
-22.89M
-20.83M
-28.87M
-23.51M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of ALT
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer